This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance.
Routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.
Will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre.
Will receive CT planning, and a cone beam CT scan for at least one fraction of radiation therapy.
Will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. As intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites.
Provides written informed consent.
Less than 18 years of age
9
Trial groupsSee each trial group below.
University of Sydney
Lead sponsor
Princess Alexandra Hospital, Brisbane, Australia
Collaborator
Calvary Mater Newcastle, Australia
Collaborator
Western Sydney Local Health District
Collaborator
Austin Health
Collaborator
Peter MacCallum Cancer Centre, Australia
Collaborator